Santa Casa de Misericordia Hospital is a major Hospital based in Porto Alegre, Brazil. It is reference in Latin America for transplants and genetic research. It is a university hospital linked to the Federal University of Health Sciences of Porto Alegre.

During the past decade, Irmandade Santa Casa de Misericordia de Porto Alegre conducted 99 clinical trials. In the 10-year time frame, 99 clinical trials started and 47 clinical trials were completed, i.e. on average, 47.5% percent of trials that started reached the finish line to date. In the past 5 years, 65 clinical trials started and 33 clinical trials were completed. i.e. 50.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Irmandade Santa Casa de Misericordia de Porto Alegre" #1 sponsor was "Janssen Research & Development, LLC" with 17 trials, followed by "Hoffmann-La Roche" with 11 trials sponsored, "Pfizer" with 9 trials sponsored, "Boehringer Ingelheim" with 8 trials sponsored and "Actelion" with 8 trials sponsored. Other sponsors include 93 different institutions and companies that sponsored additional 69 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Irmandade Santa Casa de Misericordia de Porto Alegre" #1 collaborator was "Eli Lilly and Company" with 6 trials as a collaborator, "Irmandade Santa Casa de Misericórdia de Porto Alegre" with 4 trials as a collaborator, "Brazilian Research In Intensive Care Network" with 2 trials as a collaborator, "CytoDyn, Inc." with 2 trials as a collaborator and "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 2 trials as a collaborator. Other collaborators include 82 different institutions and companies that were collaborators in the rest 86 trials.

According to Clinical.Site data, the most researched conditions in "Irmandade Santa Casa de Misericordia de Porto Alegre" are "Pulmonary Arterial Hypertension" (9 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials), "Idiopathic Pulmonary Fibrosis" (5 trials), "Asthma" (4 trials) and "Diabetes Mellitus, Type 2" (4 trials). Many other conditions were trialed in "Irmandade Santa Casa de Misericordia de Porto Alegre" in a lesser frequency.

Most popular intervention types in "Irmandade Santa Casa de Misericordia de Porto Alegre" are "Drug" (127 trials), "Other" (11 trials), "Device" (7 trials), "Biological" (6 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Docetaxel" (4 trials), "Trastuzumab" (4 trials), "Carboplatin" (3 trials) and "Dexamethasone" (3 trials). Other intervention names were less common.

The vast majority of trials in "Irmandade Santa Casa de Misericordia de Porto Alegre" are 133 trials for "All" genders, 9 trials for "Male" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Irmandade Santa Casa de Misericordia de Porto Alegre". undefined are not yet recruiting, 31 are recruiting, 24 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 65 completed trials in Irmandade Santa Casa de Misericordia de Porto Alegre, 2 suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Irmandade Santa Casa de Misericordia de Porto Alegre, 5 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 98 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 8 trials that are defined as “Not Applicable".